Back to results
US 10,106,783 B2Granted
HCV culture systems and direct-acting antiviral sensitivity
AssigneeHvidovre Hospital
InventorsYiping Li, Santseharay Ramirez Almeida, Daryl Grant Humes, Judith M. Gottwein, Jens Bukh
Life of this patent
Estimating the term…
Abstract
The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.
Claims9
An isolated nucleic acid molecule, which encodes a human hepatitis C virus, wherein the hepatitis C virus comprises:
- a 5′UTR-NS5A region derived from genotype 4a strain ED43, wherein the 5′UTR-NS5A region comprises a 5′UTR, structural proteins Core, E1 and E2, and nonstructural proteins p7, NS2, NS3, NS4A, NS4B and NS5A;
- a nonstructural protein NS5B;
- and
- a 3′UTR from strain JFH1;
- further comprising the mutations F1464L in NS3 and A1672S in NS4A according to the H77 sequence as set forth by GenBank accession number AF009606;
- and
- further comprising adaptive mutations R781W, A1309P and A1786V according to the H77 sequence as set forth by GenBank accession number AF009606.
4 more elements
Dependencies are inferred from the claim text.